Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ERα-positive breast cancer

[1]  N. Kondo,et al.  Low RAI2 expression is a marker of poor prognosis in breast cancer , 2021, Breast Cancer Research and Treatment.

[2]  I. Ellis,et al.  Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer , 2020, International journal of molecular sciences.

[3]  A. Kaneda,et al.  Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma , 2020, Scientific Reports.

[4]  I. Ellis,et al.  Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer , 2019, British Journal of Cancer.

[5]  S. Sakamoto,et al.  Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma , 2019, Scientific Reports.

[6]  C. Sander,et al.  LLGL2 rescues nutrient stress by promoting leucine uptake in ER+ breast cancer , 2019, Nature.

[7]  I. Ellis,et al.  The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer , 2019, Breast Cancer Research and Treatment.

[8]  I. Ellis,et al.  The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours , 2018, Breast Cancer Research.

[9]  J. Koo,et al.  Amino Acid Transporters and Glutamine Metabolism in Breast Cancer , 2018, International journal of molecular sciences.

[10]  F. Real,et al.  SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150 , 2016, Oncogene.

[11]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[12]  Yul Ri Chung,et al.  Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. , 2015, Human pathology.

[13]  Qian Wang,et al.  L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. , 2015, American journal of cancer research.

[14]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[15]  A. Lánczky,et al.  A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer , 2013, Breast Cancer Research and Treatment.

[16]  A. Bosserhoff,et al.  The human Lgl polarity gene, Hugl-2, induces MET and suppresses Snail tumorigenesis , 2013, Oncogene.

[17]  Carlos Caldas,et al.  A new genome‐driven integrated classification of breast cancer and its implications , 2013, The EMBO journal.

[18]  H. Putter,et al.  Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Naiki‐Ito,et al.  Age-Dependent Carcinogenic Susceptibility in Rat Liver Is Related to Potential of Gap Junctional Intercellular Communication , 2012, Toxicologic pathology.

[20]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[21]  M. Ellis,et al.  Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer , 2011, Breast Cancer Research.

[22]  M. Tsao,et al.  Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors , 2009, Oncogene.

[23]  R. Foisner,et al.  The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity , 2007, Oncogene.

[24]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Nawashiro,et al.  L‐type amino acid transporter 1 as a potential molecular target in human astrocytic tumors , 2006, International journal of cancer.

[26]  Raymond R Tubbs,et al.  Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. , 2005, Human pathology.

[27]  C. Osborne,et al.  HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[28]  M. Untch,et al.  Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Eiji Takeda,et al.  Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98)* , 1998, The Journal of Biological Chemistry.

[30]  S Detre,et al.  A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. , 1995, Journal of clinical pathology.

[31]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[32]  E. Pala,et al.  Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization for the Analysis of HER2/neu and Topoisomerase II-alpha Status in Human Breast Cancer İnsan Meme Kanserinde Topoizomeraz II-alfa ve HER2/neu Saptanmasinda İmmünohistokimya ve Floresan İn Situ Hibridizasyon Yöntemlerinin Karşil , 2010 .

[33]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .